Mangalam Drugs and Organics Ltd

NSE: MANGALAM · BSE: 532637 · Pharmaceuticals & Biotechnology · 33 announcements

Share price: ₹33.09
Market cap: ₹52.38 Cr
Revenue (annual): ₹232.1 Cr
Net profit (annual): ₹-44.40 Cr
P/E (TTM): -1.4×Sector 47.3×
Promoter holding: 35.65%+0.00% QoQ
FII holding: 0.11%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

Announcement type

All Share Pledge 5 Debt & Borrowing 5 Other Announcement 4 Management Change 4 Financial Results 3 Board Meeting Date 3 Annual General Meeting 3 Legal & Regulatory 2 Adverse Business Impact 2 Board Meeting Outcome 1

Time

All time Last 1 week Last 1 month Last 2 months Last 3 months Last 6 months Last 1 year

32 announcements with these filters

16 Apr 2026 17:27 IST BSE

Adverse Business Impact

Mangalam Drugs and Organics Adverse Business Impact

Mangalam Drugs and Organics Limited reported a combined default of ₹15.58 Crore on cash credit facilities from Bank of Maharashtra and Bank of Baroda. The defaults began in October 2025. The company stated it is making arrangements to pay the overdue amounts as soon as possible.

Value: ₹15.58 Cr

Read the filing ↗

10 Apr 2026 16:05 IST BSE

Share Pledge

Mangalam Drugs and Organics Share Pledge

Shree Kishoriju Trading and Investments Private Limited, a promoter group entity of Mangalam Drugs & Organics Limited, announced the release of 5,08,599 pledged equity shares on February 6, 2026. This release represents 3.21% of the company's total share capital, reducing the encumbered holdings of the promoter group.

Read the filing ↗